𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease

✍ Scribed by Osterman, Mark T.; Sandborn, William J.; Colombel, Jean-Frederic; Robinson, Anne M.; Lau, Winnie; Huang, Bidan; Pollack, Paul F.; Thakkar, Roopal B.; Lewis, James D.

Book ID
122316408
Publisher
Elsevier Science
Year
2014
Tongue
English
Weight
317 KB
Volume
146
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Risk–benefit analysis of adalimumab vers
Risk–benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease
✍ Edward V. Loftus Jr; Scott J. Johnson; Si-Tien Wang; Eric Wu; Parvez M. Mulani; πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 474 KB πŸ‘ 1 views

Background: Adalimumab is indicated for the treatment of moderately to severely active Crohn's disease (CD). A systematic analysis of risks and benefits of adalimumab versus traditional non-biologic therapies for patients refractory to non-biologic therapy is lacking. Methods: A base-case analysis

Family history of Crohn's disease is ass
Family history of Crohn's disease is associated with an increased risk for Crohn's disease of the pouch
✍ Bo Shen; Feza H. Remzi; Jeffrey P. Hammel; Bret A. Lashner; Charles L. Bevins; I πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 126 KB πŸ‘ 2 views

Background: Crohn's disease (CD) of the pouch can occur in patients with restorative proctocolectomy and ileal pouch-anal anastomosis originally performed for a preoperative diagnosis of ulcerative colitis (UC). CD of the pouch was often observed in patients with a family history of CD. The purpose